Overview
NRIX market data
Price History
NRIX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for NRIX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsightGlobenewswire Inc · Jul 23, 2026, 5:15 PM
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31Benzinga · Jul 22, 2026, 6:45 PM
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%Benzinga · Jul 21, 2026, 8:07 PM
Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone PaymentsBenzinga · Jul 21, 2026, 8:06 PM
Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting PeriodBenzinga · Jul 21, 2026, 8:03 PM
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34Benzinga · Jul 13, 2026, 12:21 PM
Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $34Benzinga · Jul 10, 2026, 3:45 PM
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33Benzinga · Jul 10, 2026, 1:40 PM
Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40Benzinga · Jul 10, 2026, 1:35 PM
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $32 Price TargetBenzinga · Jul 10, 2026, 12:05 PM